EUCTR2006-006913-34-HU进行中（未招募）不适用
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 568
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1.Has given written informed consent before any study-related activity is performed.
- •A study-related activity is defined as any procedure that would not have been performed during the normal management of the patient
- •2.Has completed the one-year main study, FE 200486 CS21
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Has been withdrawn/discontinued from the FE 200486 CS21 study
研究者
相似试验
进行中（未招募）
不适用
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation TherapyPatients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.MedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerEUCTR2006-006913-34-NLFerring Pharmaceuticals A/S568
已完成
3 期
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy10038364prostate cancerNL-OMON31249Ferring5
进行中（未招募）
不适用
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation TherapyPatients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.MedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerEUCTR2006-006913-34-DEFerring Pharmaceuticals A/S568
进行中（未招募）
1 期
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation TherapyPatients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.MedDRA version: 14.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-006913-34-GBFerring Pharmaceuticals A/S568
进行中（未招募）
1 期
An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy.Patients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.MedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerEUCTR2006-006913-34-CZFerring Pharmaceuticals A/S557